News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017

SBRT Offers Curative Option for Lung Cancer Patients 80 and Older

Highly targeted radiation therapy is well tolerated and effectively limits cancer spread for elderly patients with inoperable early-stage disease

SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study

March 20, 2017 — Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented at the 2017 Multidisciplinary Thoracic Cancers Symposium. The advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.

While the primary treatment for early-stage lung cancer is surgical removal of the tumor, some patients may not be able to tolerate surgery due to health status, advanced age or other factors. For these patients, the best curative option is SBRT, a specialized type of external beam radiation therapy (RT) that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor. This high degree of precision makes SBRT particularly effective at sparing surrounding healthy tissue, which is important for tumor sites near essential organs, such as the heart and lungs. Patients complete SBRT treatment in three to five days, compared with several weeks for conventional RT.

"While multiple studies and trials have established the effectiveness of SBRT for inoperable early-stage lung cancer, one of the common reasons for not giving radiation in older patients is concern about tolerating the treatment and potential side effects," said Richard J. Cassidy III, M.D., lead author of the study and a resident in radiation oncology at Emory University's Winship Cancer Institute in Atlanta. "The low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early-stage lung cancer."

Findings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015. All patients were age 80 or older at the time of their diagnosis, with a median age of 84.9 years. Forty percent of the tumors were adenocarcinomas, while 29 percent were squamous cell carcinomas and 31 percent did not have a biopsy. Fifty percent of patients who did not have a biopsy had a previous history of lung cancer. Researchers used logistic regression and proportional hazard testing to determine the association of patient, tumor and treatment characteristics to compare rates of survival, recurrence and progression and assess the influence of patient and disease characteristics. Recursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.

At two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS). CSS rates were higher for patients who were not active smokers but lower for patients who were older or had a previous lung cancer diagnosis (smoking Hazard Ratio (HR) = 0.14, p = 0.03; age HR = 1.19, p = 0.04; cancer HR = 7.75, p = 0.01). OS rates were higher for patients with higher Karnofsky Performance Status (KPS), which measures a patient's functional ability to perform ordinary tasks, such as work and self-care (HR = 0.91; p < 0.01). Researchers determined that this metric should be considered when offering SBRT in this elderly population, with certain performance status criterion (i.e., KPS ≥ 75) associated with significantly improved outcomes.

Two-year estimates of local control and regional control were 84.5 percent and 71.7 percent, respectively. Local failure was more common among patients with adenocarcinomas (HR = 6.36, p = 0.01) and less common for patients with T1 tumors (HR = 0.20, p < 0.01). Higher KPS scores were associated with lower rates of both local failure (HR = 0.92, p < 0.01) and regional failure (HR = 0.94, p < 0.01). In terms of toxicity, just over one-third of patients (34.5 percent) experienced radiation pneumonitis of any grade, with only two patients experiencing grade 3+ pneumonitis. Pneumonitis was more frequent among patients who were not actively using ace-inhibitors (Odds Ratio (OR) = 3.49, p = 0.02) and less frequent in smaller tumors (OR = 0.03, p < 0.01).

"Our study, along with other studies, helps to show that SBRT can effectively and safely add years to the lives of elderly patients who have early-stage lung cancer but cannot undergo an operation for it," said Cassidy. "Elderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age."

For more information: www.thoracicsymposium.org

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...